Destiny Pharma plc
DEST.L · LSE
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £832 | £154 | £0 |
| % Growth | -100% | 438.2% | – | – |
| Cost of Goods Sold | £3 | £4 | £6 | £6 |
| Gross Profit | -£3 | £828 | £149 | -£6 |
| % Margin | – | 99.6% | 96.1% | – |
| R&D Expenses | -£133 | £1,900 | £772 | £2,500 |
| G&A Expenses | £3,701 | £3,867 | £4,380 | £3,551 |
| SG&A Expenses | £3,624 | £2,171 | £3,326 | £1,320 |
| Sales & Mktg Exp. | -£211 | -£1,696 | -£1,054 | -£2,231 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £3,491 | £4,071 | £4,098 | £3,820 |
| Operating Income | -£3,493 | -£3,243 | -£4,104 | -£3,827 |
| % Margin | – | -390% | -2,656.4% | – |
| Other Income/Exp. Net | £178 | £111 | £48 | £30 |
| Pre-Tax Income | -£3,315 | -£3,132 | -£3,914 | -£3,797 |
| Tax Expense | -£317 | -£472 | -£599 | -£609 |
| Net Income | -£2,997 | -£2,660 | -£3,315 | -£3,188 |
| % Margin | – | -319.8% | -2,145.8% | – |
| EPS | -0.032 | -0.031 | -0.045 | -0.048 |
| % Growth | -1.9% | 31.6% | 5.6% | – |
| EPS Diluted | -0.032 | -0.031 | -0.045 | -0.048 |
| Weighted Avg Shares Out | 95,268 | 85,995 | 73,327 | 66,619 |
| Weighted Avg Shares Out Dil | 95,268 | 85,995 | 73,327 | 66,619 |
| Supplemental Information | – | – | – | – |
| Interest Income | £178 | £111 | £48 | £17 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £3 | £4 | £6 | £6 |
| EBITDA | -£3,491 | -£3,239 | -£4,098 | -£3,820 |
| % Margin | – | -389.5% | -2,652.5% | – |